WO2023182736A1 - Multi-layered tablet composite formulation and preparation method therefor - Google Patents

Abstract

The present invention relates to a multi-layered tablet composite formulation and a preparation method therefor and, to a formulation type which can improve the bioavailability of drugs and a preparation method therefor.

Description

Multilayer tablet combination preparation and method for manufacturing same

The present invention relates to a multilayer tablet combination preparation and a method for manufacturing the same.

In the development of oral drug formulations, improving dissolution and solubility is becoming increasingly important to increase drug bioavailability. In particular, niclosamide, which has a strong antiviral effect against SARS-CoV-2, the virus that recently caused the COVID-19 pandemic, and docetaxel, a representative example of an anticancer drug, are representative examples of drugs with significantly poor solubility. Because the structure of the drug itself makes it difficult for patients to absorb, its use is limited. While various studies are being attempted to solve this problem, increasing the solubility and dissolution of the drug by solubilizing the drug acts as the most important factor in drug absorption.

Additionally, among various drug delivery systems, oral drug delivery is one of the most preferred routes for in vivo administration of drugs, mainly due to patient convenience and manufacturability of dosage forms. Recent pharmaceutical research has focused on drug delivery and absorption, which can offer distinct advantages over traditional release formulations of drugs. This has the potential to maximize efficacy while minimizing administration frequency and toxicity.

In particular, due to the low absorption capacity of drugs when administered orally, absorption of drugs may occur locally in the gastrointestinal (GI) tract, and the importance of developing multilayer tablet formulations as an effective method for absorption in the intestine is emerging. Typically, the gastrointestinal (GI) tract refers to the digestive tract and includes tubes such as the esophagus, stomach, small intestine, large intestine, rectum, and anus. For example, if a drug lacks stability in gastric juices, causes irritation in the gastrointestinal tract, or needs to be targeted to specific areas, or because of pH changes throughout the GI tract, for drugs in oral dosage forms, formulation development may be necessary to improve drug absorption. The effect can be increased.

In addition, attempts to improve solubility by using polymers to solubilize drugs have continued. Accordingly, papers such as Contribution to the Improvement of an Oral Formulation of Niclosamide, an Antihelmintic Drug Candidate for Repurposing in SARS-CoV-2 and Other Viruses (co-authored by Eduardo Jose Barbosa and 5 others) also showed that the solubility of drugs such as niclosamide was improved. It discloses the use of polymer materials to do this. Although the disclosed papers and the like disclose that the solubility of niclosamide can be improved when polymer materials are used, the improved solubility range can improve the actual absorption rate of niclosamide in the body and substantially demonstrate its antiviral effect. There is still a problem in that it has not achieved a significant effect.

In addition, single-layer immediate-release tablets, which have been commonly used as existing oral dosage forms, have a problem in that it is difficult to control the absorption of the drug immediately after oral administration due to the nature of the preparation. In particular, in the case of drugs that are mainly absorbed in specific parts of the body, it is difficult to control the release, dispersion and absorption of the drug in the form of a single-layer immediate-release tablet, making oral administration difficult as it does not show the drug's effect properly. Therefore, single-layer preparations generally allow rapid absorption of the drug without specific targeting for therapeutic action, but there is a problem in that it is difficult to improve the low absorption rate of the drug.

[Prior art]

Contribution to the Improvement of an Oral Formulation of Niclosamide, an Antihelmintic Drug Candidate for Repurposing in SARS-CoV-2 and Other Viruses (co-authored by Eduardo Jose Barbosa and 5 others)

The present invention relates to a multilayer tablet composite preparation for improving the bioavailability of a drug or a pharmaceutically acceptable salt thereof, comprising at least one of a drug or a pharmaceutically acceptable salt thereof, a crystallization inhibitor, and a polymer for controlling the drug release rate. A drug-containing layer formed from a first mixing portion containing; and a floating layer formed of a second mixing portion containing at least one of a polymer polymerized with poly(meth)acrylate, a polymer polymer polymerized with acrylic acid, and a swellable polymer.

In addition, the present invention is a multilayer tablet complex that can provide more effective pharmaceutical effects by increasing the residence time in the stomach to maximize the absorption rate of the drug in the body and improving the absorption of the drug in the stomach and small intestine. The purpose is to provide a manufacturing method for the preparation.

The present invention provides a drug-containing layer formed of a first mixing portion containing a drug or a pharmaceutically acceptable salt thereof, a crystallization inhibitor, and a polymer for controlling the drug release rate; and a floating layer formed from a second mixing portion containing at least one of a polymer polymerized with poly(meth)acrylate, a polymer polymer polymerized with acrylic acid, and a swellable polymer.

In addition, the present invention includes the steps of dissolving a crystallization inhibitor and a drug in an organic solvent to prepare a first dissolved product; preparing a powder of the first melt by drying the first melt; Forming a drug-containing layer using the powder of the first lysate; And preparing a multi-layer tablet forming a floating layer by compressing a second mixed portion containing at least one of a polymer polymer polymerized with poly(meth)acrylate and a polymer polymer polymerized with acrylic acid and a swellable polymer in the drug-containing layer. The purpose is to provide a method for manufacturing a multi-layered tablet combination preparation comprising a.

The present invention provides a gastric retentive drug delivery system (GRDDS) function that can manipulate the release of API in the body to control the therapeutic efficacy of the drug, improve patient compliance, and reduce the frequency of administration through a multilayer tablet combination formulation. It has the effect of providing

In addition, the multilayer tablet combination preparation of the present invention can solve the problem of low drug absorption rate or gastrointestinal tract irritation, which is a problem during oral administration, and when targeting a specific area, it can be used due to changes in drug absorption rate due to pH changes throughout the GI tract. It can provide effects that can solve problems.

Figure 1 is a photograph of the multilayer tablet combination preparation of the present invention.

Figure 2 is a graph of the results of in vivo pharmacokinetic analysis for beagles.

Figure 3 is a graph of the results of in vivo pharmacokinetic analysis for minipigs. Figure 4 is a graph of AUC values among the in vivo pharmacokinetic analysis results for minipigs.

Figure 5 is a graph of the results of in vivo pharmacokinetic analysis for minipigs.

Figure 6 is a graph of AUC values among the in vivo pharmacokinetic analysis results for minipigs.

Figure 7 is a graph of the results of in vivo pharmacokinetic analysis of beagles in Examples 10 and 11 and Comparative Examples 5 and 6.

Figure 8 is a graph of AUC values among the in vivo pharmacokinetic analysis results for beagles in Examples 10 and 11 and Comparative Examples 5 and 6.

Figure 9 is a photograph of a three-layer tablet manufactured by the method of Example 12 as an example of a multi-layer tablet.

The present invention is a first drug containing at least one of a drug or a pharmaceutically acceptable salt thereof, a crystallization inhibitor, and a polymer for controlling the drug release rate that can improve the problem of weakening the effect of the drug in the body due to lower absorption rate when administered orally. A drug-containing layer formed as a mixing portion; and a second mixing portion containing at least one of a polymer polymerized with poly(meth)acrylate, a polymer polymer polymerized with acrylic acid, and a swellable polymer.

In the present invention, the second mixing portion containing at least one of a polymer polymerized with poly(meth)acrylate, a polymer polymer polymerized with acrylic acid, and a lipophilic polymer is configured to provide floatability to the multilayer tablet composite preparation.

The polymer obtained by polymerizing acrylic acid may be one or more types selected from carbomer copolymer type, carbomer homopolymer type, and ammonio methacrylate copolymer type (AMMONIO METHACRYLATE COPOLYMER TYPE). More specifically, the carbomer copolymer type may be a carbomer copolymer type (CARBOMER COPOLYMER TYPE (ALLYL PENTAERYTHRITOL CROSSLINKED)) in which allyl pentaerythritol is crosslinked, and the carbomer homopolymer type may be a carbomer copolymer type in which allyl pentaerythritol is crosslinked. CARBOMER HOMOPOLYMER TYPE (ALLYL PENTAERYTHRITOL CROSSLINKED) or allyl sucrose cross-linked carbomer homopolymer type (CARBOMER HOMOPOLYMER TYPE (ALLYL SUCROSE CROSSLINKED)), allyl pentaerythritol cross-linked carbomer homopolymer type It may be a polymer type (CARBOMER HOMOPOLYMER TYPE (ALLYL PENTAERYTHRITOL CROSSLINKED)). The carbomer copolymer type, carbomer homopolymer type, and ammonio methacrylate copolymer type (AMMONIO METHACRYLATE COPOLYMER TYPE) can be classified into A, B, and C, respectively. Carbomers belonging to the above are restricted. It can be used without.

The polymer polymer in which poly(meth)acrylate is polymerized is specifically a polymer polymer in which methacrylate is polymerized, a polymer polymer in which ethyl acrylate is polymerized, a polymer polymer in which methacrylate and ethyl acrylate are polymerized, and ethylene glycol. This polymer polymer, a polymer polymer polymerized with methacryl acid and methyl methacrylate, a polymer polymer polymerized with ethylene glycol, a polymer polymer polymerized with ammonium methacrylate, dimethylaminoethyl, methacrylate, and butyl methacrylate. It may be one or more types selected from polymers in which crylate is polymerized. More specifically, the polymer polymer obtained by polymerizing poly(meth)acrylate is METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER) (1:1) TYPE A, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER) (1:1) TYPE B, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER) (1:1) TYPE C, METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1) TYPE A, METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1) TYPE B, METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1) TYPE C, METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2) TYPE A, METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2) TYPE B, METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2) TYPE C, ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER (2:1; 600000 MW) TYPE A, ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER (2:1; 600000 MW) TYPE B, ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER (2:1; 600000 MW) TYPE C, AMMONIO METHACRYLATE COPOLY MER TYPE A, AMMONIO METHACRYLATE COPOLYMER TYPE B, AMMONIO METHACRYLATE COPOLYMER TYPE C, DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER TYPE A, DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYL ATE COPOLYMER TYPE B and DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER TYPE C There may be one or more types selected. The polymer obtained by polymerizing the poly(meth)acrylate may be more specifically a Eudragit-based polymer. The types of Eudragit series polymers are listed in Table 1 below.

product name	IUPAC name
Eudragit RL 100 Eudragit RL PO Eudragit RL 30 D Eudragit RL 12.5	Poly(ethyl acrylate-co-methyl methacrylate-co-trimethyl ammonioethyl methacrylate chloride)1:2:0.2 (AMMONIO METHACRYLATE COPOLYMER TYPE A)
Eudragit RS 100 Eudragit RS PO Eudragit RS 30 D Eudragit RS 12.5	Poly(ethyl acrylate-co-methyl methacrylate-co-trimethyl ammonioethyl methacrylate chloride)1:2:0.1(AMMONIO METHACRYLATE COPOLYMER TYPE B)
Eudragit NE 30D Eudragit NE 40D Eudragit NM 30D	(ETHYL ACRYLATE AND METHYL METHACRYLATE COPOLYMER(2:1;75000)
Eudragit L 30D-55 Eudragit L 100-55 Eudragit L 100/ 12.5	Poly(methacrylic acid-co-methyl methacrylate)1:1 (METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER (1:1) TYPE A) METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER (1:1)
Eudragit S 100Eudragit S 12.5	Poly(methacrylic acid-co-methyl methacrylate)1:2 (METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER (1:2))
Eudragit L 30D-55Eudragit L 100-55	Poly(methacrylic acid-co-ethyl methacrylate)1:1
Eudragit E 100Eudragit E 12.5 Eudragit E PO	Poly(buthylmethacrylate-co-(2-dimetnylaminoethyl) methacralte-co-methyl methacrylate)1:2:1 (DEMETHYLAMINOETHYL METHACRYLATE-BUTHYL METHACRYLATE-METHYL METHACRYLATE COPOLYMER)

In addition, the polymer polymer polymerized with poly(meth)acrylate or the polymer polymer polymerized with acrylic acid each has a tap density of 0.01 g/mL to 1.0 g/mL, more preferably 0.025 g/mL to 0.7. In g/mL, it plays a role in providing floating properties to the drug-containing preparation when forming a multilayer tablet complex preparation. If the tap density range of the poly(meth)acrylate-polymerized polymer or the acrylic acid-polymerized polymer does not fall within the above-mentioned range, it will not float, or even if it floats and stays, it will sink within 30 minutes, causing initial damage. Drug release and absorption may not occur. In addition, when a floating base exceeding the above tap density range is used, a phenomenon in which the drug is not continuously released (trapping) occurs when the drug stays in the stomach, and the expected effect may not be achieved.

In the present invention, the swellable polymer can be used without limitation as long as it is a polymer that can provide floating properties to the floating layer, but includes methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, sodium carboxymethylcellulose, sodium alginate, It may be one or more selected from polyethylene oxide, pregelatinized starch, carrageenan, xanthan gum, locust bean gum, and guar gum.

In the present invention, the drug includes Niclosamide, Closantel, rafoxanide, oxyclozanide, Artesunate, Tilorone, and cyclosporine ( Cyclosporine, perhexiline maleate, loperamide, mefloquine, amodiaquine, proscillaridin, phenazopyridine, digitoxin ), penfluridol, clomiphene, toremifene, digoxin, hexachlorophene, hydroxyprogesterone, thioridazine, salinomycin ( salinomycin, quinacrine, eltrombopag, cepharanthine, ciclesonide, ceritinib (LDK378), dihydrogambogic acid ), osimertinib (AZD-9291), isopomiferin, anidulafungin (LY303366), osajin, lustrombopag, isosajin , gilteritinib, berbamine, ebastine, tetradrine, abemaciclib (USAN), ivacaftor, bazedoxifene ), mequitazine, triparanol, droloxifene, dronedarone, chloroquine, hydroxychloroquine, lopinavir, favipyra It may be one or more types of drugs selected from favipiravir, atazanavir, dexamethasone, etc., that can be used as antiviral drugs, antibiotics, malaria drugs, painkillers, etc. Additionally, Docetaxel, Paclitaxel, Cabazitaxel, Etoposide, Topotecan, Idarubicin, Fluorouracil, and Abiraterone ), Axitinib, Bosutinib, Cabozantinib, ceritinib, dabrafenib, erlotinib, lapatinib, midostaurin Anticancer drugs such as midostaurin, neratinib, nilotinib, nintedanib, pazopanib, sonidegib, and trametinib, or ascorbic acid (Ascorbic acid), vitamin A, lipoic acid, pramipexole, allopurinol, pentoxifylline, melatonin, probucol, quercetin , transcrocetinate, acetylcysteine, nicaraven, lodoxamide, 4-n-butylresorcinol, tocopherol, Bakuchiol, (+)-catechin, curcumin, hydroxytyrosol, phytol, resorcinol, carthamine ), luteolin, corilagin, resveratrol, retinol, rutin, hydroquinone, asiaticoside, madecassoside, gin Ginsenoside, borneol, diosmetin, aspalathin, eugenol, mangostin, pelargonidin, cyanidin, Delphinidin, peonidin, petunidin, malvidin, lutein, quercetin, adenosine, ascorbyl palmitate, Ascorbyl glucoside, pyridoxine, thiamine, saponin, secoisolariciresinol, matairesinol, pinoresinol, medire Medioresinol, lariciresinol, syringaresinol, artigenin, enterolactone, enterodiol, arachidonic acid, abietic acid ( abietic acid, abscisic acid, α-lipoic acid, azelaic acid, caffeic acid, hydroxybenzoic acid, protocatechuic acid , ellagic acid, ferulic acid, fulvic acid, oleanolic acid, phenolic acid, hydroxycinnamic acid, vanillic acid. Acid, protocatechuic acid, salvianic acid, sinapic acid, tranexamic acid, valeric acid, Veratric Acid , chlorogenic acid, asiatic acid, madecasic acid, suberic acid, hyaluronic acid, ursolic acid, ascorbic acid. acid), salvianolic acid B, pyridine-3-carboxylic acid, ascorbyl palmitate, ascorbyl glucoside, carnitine , pantothenic acid, biotin, folic acid, alliin, glutathione, serine, glycine, alanine, avenanthramide ), threonine, cysteine, valine, leucine, methionine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid (aspartic acid), glutamic acid, asparagine, glutamine, histidine, lysine, arginine, decanal, retinaldehyde, cinnamaldehyde (cinnamaldehyde), catechin-aldehyde, coniferyl aldehyde, syringaldehyde, vanillin, edaravone, idebenone, coenzyme Q10 ), ubiquinone, mitoQ, astaxanthin, caffeine, paraxanthine, theophylline, matairesinol, physcion , propafenone, coumarin, genistein, chalcone, naringenin, bergenin, amentoflavone, Biochanin A , riboflavin, sesamin, etc. Among anti-inflammatory and antioxidant agents such as dextran sulfate, ferrous sulfate, ferulic acid-4-O-sulfate, and ascorbyl sulfate, There may be one or more types selected.

The multilayer tablet combination preparation of the present invention can be effectively applied to poorly soluble drugs among the above drugs, and more preferably may be one or more types selected from the halogenated salicylanilide series and taxane series drugs. The halogenated salicylanilide-based drugs may include niclosamide, closantel, lapoxanide, and oxyclozanide, and the taxane-based drugs include docetaxel, paclitaxel, and cabazitaxel ( Cabazitaxel), etc.

In the present invention, pharmaceutically acceptable salts refer to salts commonly used in the pharmaceutical industry, for example, inorganic ionic salts made of calcium, potassium, sodium and magnesium, hydrochloric acid, nitric acid, phosphoric acid, bromic acid, and iodine. Inorganic acid salts prepared from acids, perchloric acid, sulfuric acid, etc.; Acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid. Organic acid salts made from acids, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid, etc.; Sulfonic acid salts made from methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, etc.; Amino acid salts made from glycine, arginine, lysine, etc.; and amine salts prepared from trimethylamine, triethylamine, ammonia, pyridine, picoline, etc., but the types of salts meant in the present invention are not limited by these salts listed.

The multilayer tablet combination preparation of the present invention is within the scope of the present invention if the drug-containing layer and the floating layer are formed in two or more layers, and changes or substitutions in the stacking order or coating method are within the scope of the present invention. It is self-evident and falls within the scope of the present invention.

Specifically, the multilayer tablet combination preparation of the present invention may further include an intermediate layer between the drug-containing layer and the floating layer, or may further include a third layer laminated on top and/or below the drug-containing layer and the floating layer. In one embodiment, Figure 9 is a floating layer - drug-containing layer - floating layer, which is formed in the form of a three-layer multilayer tablet with floating layers formed on the top and bottom of the drug-containing layer, respectively. The intermediate layer and/or the third layer may be formed of the same or different components as the drug-containing layer or floating layer listed in the present invention.

The combination preparation in the present invention can be used without limitation as long as it is formulated for oral administration. Specifically, it may mean tablets, capsules, granules, etc., and if the tablet form consists of two or more layers, it falls within the scope of the present invention. Specifically, the tablets include orally disintegrating tablets, chewable tablets, effervescent tablets, dispersion tablets, dissolving tablets, etc., and the granules may refer to forms such as hard capsules and soft capsules.

In addition, the tablets in the present invention are made by homogenizing the drug (or main ingredient) with additives such as excipients, binders, and disintegrants, and then compression molding them as is, or by adding the main ingredient and lubricant to pre-made granules to homogenize them. Compression molding method: add additives such as excipients, binders, and disintegrants to the main ingredients to make them homogeneous; add water or a solution containing the binder to form granules in an appropriate manner; then add a lubricant, mix, and compression mold. This may mean manufacturing by adding additives such as excipients, binders, and disintegrants to the powder and mixing it evenly, then moistening it with a solvent and molding it into a certain shape, or putting it in a certain mold and then drying it.

In addition, it is obvious that the combination preparation of the present invention is within the scope of the present invention in addition to the multi-layered tablet form. For example, design of film-coated tablets thinly coated using polymer compounds, sugar-coated tablets coated with a coating containing sugars or sugar alcohols on uncoated tablets, and press-coated tablets manufactured by coating the inner core tablet with an outer layer of different composition. Changes are within the scope of the combination preparation of the present invention.

In the present invention, the first mixing part and/or the second mixing part of the multilayer tablet combination preparation may further include a metal hydroxide or metal oxide. The metal hydroxide may be a compound represented by Formula 1 or 2, and the metal oxide may be represented by Formula 3. Among the compounds belonging to the formulas 1 to 3, magnesium oxide (MgO), hydrotalcite (Mg ₆ Al ₂ CO ₃ (OH) ₁₆ ·4H ₂ O; Mg ₂ Al ₁ CO _0.5 (OH) ₄ ·nH ₂ O; Mg _2.56 Al ₁ CO _0.5 (OH) _7.12 ·0.12H ₂ O; Mg _2.41 Al ₁ CO _0.5 (OH) _6.82 ·0.12H ₂ O; Mg _0.74 Al _0.26 (OH) ₂ Cl _0.24 ·0.58H ₂ O), magnesium hyde It may be preferable to include oxide (Mg(OH) ₂ ) or a mixture thereof because it is most effective in improving the solubility of the drug.

[Formula 1]

[(M ²⁺ _(10-x) M ³⁺ _x (OH) _m )((A ^n- ) _z )]yH ₂ O

(In Formula 1, M ²⁺ is a divalent metal cation selected from the group consisting of Mg ²⁺ , Ni ²⁺ , Cu ²⁺ , Co ²⁺ and Zn ²⁺ , and M ³⁺ is Al ³⁺ , Fe ^{3 +} is a trivalent metal cation selected from the group consisting of V ³⁺ , Ti ³⁺ , Mn ³⁺ and Ga ³⁺ , x is a number ranging from 0 to 10, and m is a number ranging from 0 to 20. is a number, and A is an anion selected from the group consisting of CO ₃ ^2- , NO ₃ ^- , Br ^- , Cl ^- , SO ₄ ^2- , HPO ₄ ^2- and F ^- , and n is the charge number of anion A. , n is a number ranging from 0.5 to 5, z is a number ranging from 0 to 5, and y is a positive number greater than or equal to 0.)

[Formula 2]

[(M ²⁺ (OH) _2-x )((A ^n- ) _z )]yH ₂ O

(In Formula 2, M ²⁺ is a divalent metal cation selected from the group consisting of Mg ²⁺ , Ni ²⁺ , Cu ²⁺ , Co ²⁺ and Zn ²⁺ , and x has a range of 0 to 2 number, A is an anion selected from the group consisting ^of CO ₃ ^2- , NO _3- ^, Br- ^, Cl-, SO ₄ ^2- , HPO ₄ ^2- and ^F- , n is the charge number of anion A, n is a number in the range of 0 to 2, z is a number in the range of 0 to 1, and y is a positive number of 0 or more than 0.)

[Formula 3]

[(M ²⁺ (O) _2-x )((A ^n- ) _z )]yH ₂ O

(In Formula 3, M ²⁺ is Mg ²⁺ , Ni ²⁺ , Cu ²⁺ or Zn ²⁺ , x is a number ranging from 0 to 2, and A is CO ₃ ^2- , NO ₃ ^- , Br ^- , Cl ^- , SO ₄ ^2- , HPO ₄ ^2- or F ^- , n is the charge number of anion A, n is a number ranging from 0 to 2, and z is 0 to 1. It is a number with a range below, and y is 0 or a positive number greater than 0.)

In the present invention, a crystallization inhibitor may refer to a polymer that can delay the return of a compound to its crystalline form when dissolved in a solvent, etc., so as to maintain the amorphous or non-crystalline form of each compound when the drug is dissolved in a solvent. By delaying the crystallization time of the drug by loading the drug into the crystallization inhibitor, the solubility of the drug in the body can be increased, thereby increasing the blood concentration of the drug.

Specifically, the crystallization inhibitor includes polyvinyl pyrrolidone-based compounds, poloxamer-based compounds, cellulose-based compounds, polyethylene glycol-based compounds, polyoxyethylene sorbitan fatty acid esters compounds, and lecithin-based compounds. ) compounds, fatty acid compounds, glycerol fatty acid esters compounds, sorbitan fatty acid esters compounds, oils, sodium dodecyl sulfate, sodium stearyl puma It may be sodium stearyl fumarate, stearic acid, lauric acid, and carrageenan.

In addition, the polyvinyl pyrrolidone-based compounds include polyvinylpyrrolidone K10 (MW 8000-10,000), polyvinylpyrrolidone K12 (MW 11,000-12,000), polyvinylpyrrolidone K15 (MW 14,000-18,000), and polyvinylpyrrolidone K17 (MW 14,000-18,000). 000), polyvinylpyrrolidone K18 (MW 14,000~18,000), polyvinylpyrrolidone K25(MW 20,00~25,000), polyvinylpyrrolidone K30(MW30,00~40,000), polyvinylpyrrolidone K60(MW 50,00~60,000) and polyvinylpyrrolidone K90(MW80,00~90,00) 00) In a group consisting of There may be one or more types selected. In the above, MW means molecular weight.

In addition, the poloxamer-based compounds include poloxamer 101, poloxamer 105, poloxamer 105 benzoate, poloxamer 108, poloxamer 122, poloxamer 123, poloxamer 124, poloxamer 181, and poloxamer 182. , poloxamer 182 dibenzoate, poloxamer 183, poloxamer 184, poloxamer 185, poloxamer 188, poloxamer 212, poloxamer 215, poloxamer 217, poloxamer 231, poloxamer 234, poloxamer 235, poloxamer 237, Poloxamer 238, Poloxamer 282, Poloxamer 284, Poloxamer 288, Poloxamer 331, Poloxamer 333, Poloxamer 334, Poloxamer 335, Poloxamer 338, Poloxamer 401, Poloxamer 402, Poloxamer 403 and It may be one or more types selected from the group consisting of poloxamer 407, etc., and poloxamer 407 may be more preferable. The weight average molecular weight of the poloxamer-based compound described above may be 5,000 to 500,000.

In addition, the cellulose-based compounds include hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose, hydroxypropylcellulose (HPC), carboxymethylcellulose (CMC), and ethyl cellulose ( It may be one or more selected from the group consisting of ethylcellulose (EC), methylcellulose (MC), and cellulose acetate (CA). The weight average molecular weight of the above-mentioned cellulose-based compound may be 5,000 to 500,000.

In addition, the polyethylene glycol-based compounds include polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 500, polyethylene glycol 1000, polyethylene glycol 1400, and polyethylene glycol 1500. , polyethylene glycol 4000, polyethylene glycol 8000, polyethylene glycol 10000, and methoxy polyethylene glycol 550. The weight average molecular weight of the above-described polyethylene glycol-based compound may be 5,000 to 500,000.

In the case of the polyoxyethylene sorbitan fatty acid ester system, the most representative commercially available Tween surfactant is an ester bonded form of fatty acid and ethylene oxide. More specifically, polyoxyethylene sorbitan monolaurate (Tween 20), polyoxyethylene sorbitan monopalmitate (Tween 40), polyoxyethylene glycol sorbitan monostearate (polyethylene glycol sorbitan) monostearate; Tween 60), Tween65, polyoxyethylene sorbitan monooleate (Tween80), and polyoxyethylene sorbitan trioleate (Tween85).

In addition, the lecithin-based compound refers to lecithin and its derivatives, including phospholipids, phosphatidyl choline, mixed phospholipids, sodium cholate, and hydroxylase. It may be hydroxylated phospholipids, hydroxylated lecithin, etc.

In addition, the fatty acid-based compounds include butyric acid, caproic acid, caprylic acid, capric acid, stearic acid, and lauric acid. , oleic acid, myristoleic acid, palmitoic acid, oleic acid, linoleic acid, α-linolenic acid, γ-linolenic acid, gadoleic acid, eicosadienoic acid, eicosapentanoic acid, arachidoic acid, erucic acid, docosadienoic acid, docostrienoic acid, docosapentaenoic acid, docosahexaenoic acid, It may be adrenic acid, nervonic acid, etc.

In addition, the glycerol fatty acid esters include polyglycerol fatty acid esters, polyglycerol polyricinoleate, polyoxyethyleneglycerol triricinoleate, and cremophor EL. It may be, etc.

Additionally, the sorbitan fatty acid ester may be sorbitan monolaurate (Span 20), sorbitan monooleate (Span 80), etc.

Additionally, the oils may be soybean, MCT oil (Medium-Chain Triglyceride), caster oil, etc. It is preferable that the above-mentioned crystallization inhibitor is further included because it can improve the solubility and dispersibility of the drug.

The polymer for controlling the drug release rate is a substance that can help control the drug release rate when formulating a drug, and includes calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, ethyl cellulose, polyethylene oxide, and leucostvine gum. , Guar gum, Bofill, polyvinyl acetate, polyvinylpyrrolidone-polyvinyl acrylate copolymer, polyvinyl alcohol-polyethylene glycol copolymer, polyvinylpyrrolidone-polyvinylacetate copolymer, bentonite, hectorite, Carrageenan, It may be Ceratonia, Cetostearyl alcohol, hydroxypropyl starch, magnesium aluminum silicate, polydextrose, poly(methyl vinyl ether/maleic anhydrose), propylene glycol alginate, and saponate. .

The first mixing part and/or the second mixing part of the present invention may further include one or more compounds selected from the group consisting of an enteric coating agent, a foam generator, and a swelling excipient.

In the present invention, the enteric coating refers to a material that coats the drug so that the drug is released when it passes through the intestinal tract instead of being released in the stomach. Enteric coating can be used to select the area in the intestine where the drug is released. In particular, in the case of niclosamide, the bioavailability varies over time depending on the pH of each area in the intestine, especially in the stomach due to recrystallization by gastric juice. Absorption of the drug is significantly reduced. Accordingly, the use of an enteric coating agent may be desirable in that it is possible to select an optimized formulation for drugs with different absorption rates depending on the pH of the organ by suppressing recrystallization of the drug in the stomach using an enteric coating agent. Specifically, the enteric coating agent may be hydroxypropyl-methyl cellulose phthalate, zein, shellac, etc.

The bubble generator may be sodium carbonate, sodium bicarbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, and citric acid. The bubble generator may be used to form a floating layer by being included in the second mixing part with the polymer polymer polymerized with the poly(meth)acrylate of the present invention and the polymer polymer polymerized with acrylic acid.

The swelling excipients include carboxymethyl cellulose, natural cellulose, pectin, hyaluronic acid, polyacrylate, polyethylene oxide, polypropylene oxide, monosaccharides, methacrylic acid-ethyl acrylate copolymers, shellacs, and carbopolymers (carbomer, carboxyvinyl polymer). ) and polyvinyl alcohol, hydroxypropyl methyl cellulose phthalate-based compounds, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl acetate succinate, carboxymethyl cellulose, carboxymethyl ethyl cellulose. , cellulose acetate phthalate compounds, hydroxypropyl cellulose compounds, ethyl cellulose compounds, methylcellulose compounds, polyvinyl acetate phthalate, silicon dioxide, calcium silicate, lactose, starch, lactose, mannitol, kaolin inorganic salt, powdered sugar. , powdered cellulose derivatives, microcrystalline cellulose, etc.

When the combination preparation of the present invention is formulated in the form of film coating, semi-permeable membrane coating, water-insoluble coating, tablet, double tablet, stomach retention tablet, etc. using a coating agent, the blood concentration of the drug is very high. Since it has been confirmed, a coating layer may be further included in that the formation of the coating agent may be helpful for effects such as improving the solubility of the drug.

In addition, the combination preparation of the present invention may additionally contain ingredients that do not increase medicinal efficacy but are commonly used in pharmaceutical combination preparations to improve smell, taste, vision, etc. In addition, the multilayer tablet combination preparation of the present invention may additionally contain pharmaceutically acceptable additives. Pharmaceutically acceptable additives may be, for example, excipients, lubricants, binders, and disintegrants. Specifically, pharmaceutically acceptable additives may be, for example, starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicone, etc. Dioxide, calcium hydrogen phosphate, lactose, mannitol, taffy, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba lead, synthetic aluminum silicate, stearic acid, magnesium stearate. , aluminum stearate, calcium stearate, white sugar, dextrose, sorbitol, and talc, but are not limited thereto.

The present invention includes the steps of dissolving a crystallization inhibitor and a drug in an organic solvent to prepare a first dissolved product; preparing a powder of the first melt by drying the first melt; Forming a drug-containing layer using the powder of the first lysate; And manufacturing a multilayer tablet that forms a floating layer by compressing a second mixing portion containing at least one of a polymer polymer polymerized with poly(meth)acrylate and a polymer polymer polymerized with acrylic acid in the drug-containing layer. , provides a method for manufacturing a multilayer tablet combination preparation.

In addition, the present term includes the steps of dissolving a crystallization inhibitor and a drug in an organic solvent to prepare a first dissolved product; Dissolving one or more of magnesium oxide, hydrotalcite, and magnesium hydroxide in the first melt; preparing a powder of the first melt by drying the first melt; Forming a drug-containing layer using the powder of the first lysate; And manufacturing a multilayer tablet that forms a floating layer by compressing a second mixed portion containing at least one of a polymer polymer polymerized with poly(meth)acrylate and a polymer polymer polymerized with acrylic acid in the drug-containing layer. A method for manufacturing a multilayer tablet combination preparation is provided.

In addition, the present invention includes the steps of dissolving a crystallization inhibitor and a drug in an organic solvent to prepare a first dissolved product; preparing a powder of the first melt by drying the first melt; Preparing a mixture by mixing one or more of magnesium oxide, hydrotalcite, and magnesium hydroxide into the powder; Forming a drug-containing layer using the mixture; And manufacturing a multilayer tablet that forms a floating layer by compressing a second mixing portion containing at least one of a polymer polymer polymerized with poly(meth)acrylate and a polymer polymer polymerized with acrylic acid in the drug-containing layer. , provides a method for manufacturing a multilayer tablet combination preparation.

The organic solvent may be one or more selected from ethanol, methanol, propanol, butanol, and acetonitrile, and any organic solvent may be used without limitation. However, in terms of improving reactivity, an anhydrous organic solvent may be more preferable, and anhydrous ethanol may be most preferable.

In the production method of the present invention, water can be further included in the organic solvent or water can be used as needed.

In the case of the above tableting method, any conventional method of tableting a two-layer tablet can be used without limitation. More specifically, a tablet press can be used. The tableting method includes first forming a drug-containing layer in a first mixing section to form a multilayer tablet; Securing space for forming a floating layer on the drug-containing layer; forming a floating layer on the drug-containing layer; And it may include the step of applying tableting pressure to the floating layer. The expression of the first lysate, drug-containing layer, and floating layer in the above production method is an arbitrary order, and the order of preparing the first lysate, drug-containing layer, and floating layer may be changed or replaced, and such substitution or order may be performed. Changes to are obvious to those skilled in the art and fall within the scope of the present invention.

In one embodiment, the drug-containing layer may be formed from the first mixing part, and the floating layer may be formed from the second mixing part. In the step of forming the drug-containing layer, the step may include filling the first mixture into the container of the tablet press and then pre-compressing the filled first mixture. Filling at this time allows the first mixing part to freely fall into the container, and can create a space for filling the second mixing part through preload. After the drug-containing layer is formed, a floating layer is formed with a second mixing portion thereon, and the second mixing portion can also be formed by freely falling on the drug-containing layer. In another embodiment, a drug-containing layer may be formed in a tablet press using the second mixing unit, and a floating layer may be formed on the drug-containing layer using the first mixing unit.

In the present invention, the multilayer tablet composite preparation may further include the step of dry mixing the first dissolved powder with one or more metal oxides or metal hydroxides selected from Formulas 1 to 3. More preferably, the at least one metal oxide or metal hydroxide selected from Formulas 1 to 3 may be magnesium oxide (MgO). When mixing the magnesium oxide, the solubility of the drug can be significantly improved, which is desirable in that the desired bioavailability improvement effect can be obtained.

In the present invention, the ratio of the drug-containing layer and the floating layer in the multilayer tablet combination preparation may be 1:9 to 9:1 by weight, and more specifically, 2:8 to 8:2.

The multilayer tablet combination preparation of the present invention contains 0.1 to 40% by weight of the drug or a pharmaceutically acceptable salt thereof, 0.2 to 80% by weight of a crystallization inhibitor, and 0.5 to 0.5% by weight of a swellable polymer when the total weight of the first mixing portion is 100% by weight. It may contain 80% by weight. The multilayer tablet composite preparation may further include 0.1 to 40% by weight of one or more types selected from the group consisting of compounds represented by Formulas 1 to 3, and may be selected from the group consisting of enteric coating agents, foam generators, and swellable excipients. It may further include 1 to 30% by weight of one or more selected substances.

The multilayer tablet composite preparation of the present invention contains 80% of at least one of a polymer polymerized with poly(meth)acrylate, a polymer polymer polymerized with acrylic acid, and a swellable polymer when the total weight of the second mixing portion is 100% by weight. It may contain from 100% by weight.

The multilayer tablet combination preparation of the present invention may be for anti-inflammatory, antiviral, and/or anticancer purposes.

In the present invention, anti-inflammatory means having the effect of alleviating inflammatory reactions caused by infectious, traumatic, endogenous, inflammatory, degenerative, or autoimmune causes. This includes diseases such as ulcerative colitis, inflammatory disease, Crohn's disease, and viral enteritis.

In the present invention, antiviral use refers to malaria infection or Epstein Barr Virus (EBV), hepatitis B virus, hepatitis C virus, HIV, HTLV 1, and Varicella that have an antiviral effect and cause viral diseases. -Corona viruses and/or variants thereof, such as Varicella-Zoster Virus (VZV), Human Papilloma Virus (HPV), SARS-CoV and/or SARS-CoV2 More specifically, regarding viruses such as omicron, rhinovirus, adenovirus, RS virus, parainfluenza virus, RS virus, etc., which cause colds or respiratory diseases, and other retroviruses. It means that it has a virus proliferation inhibitory effect and antibiotic function.

In addition, in the present invention, anticancer use mainly means having anticancer activity by acting directly on DNA to block the replication, transcription, and translation processes of DNA, or by interfering with the synthesis of nucleic acid precursors in the metabolic pathway and inhibiting cell division. . Specifically, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, and lymphatic vessels. Lymphangiosarcoma, lymphangioendothelioma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer (pancreatic cancer), breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma (sweat gland carcinoma), sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, Renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms tumor, cervical cancer (cervical cancer), testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma (astrocytoma), medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma cancer, including meningioma, melanoma, neuroblastoma, and retinoblastoma, and carcinoma produced in breast, prostate, kidney, bladder, or colon tissue; Adipocyte tumors, such as lipoma, fibrolipoma, lipoblastoma, lipomatosis, hibemoma, hemangioma, and/or liposarcoma. It means that it has a therapeutic effect on neoplastic diseases that occur in adipose tissue.

The multilayer tablet combination preparation of the present invention can be administered at a dose of 0.001 mg/kg to 500 mg/kg, once to eight times a day, and depending on the course, once to three times a day, once to three times a day. It can be administered once, 1 to 3 times in 4 days, or 1 to 3 times in 5 days.

The multilayer tablet combination preparation of the present invention can be optimized for administration by oral administration (oral administration).

Example 1: Preparation of multilayer tablet

In a round bottom flask, add 1g of Niclosamide to a solution of 4g of PVP in 50mL of absolute ethanol, stir for about 1 hour, and then dry. 5 g of dried NIC-PVP and 2 g of MgO are dry mixed (first mixing section). The second mixing part is manufactured using carbomer (947). For tableting of multi-layer tablets, a drug layer is formed with 0.225 g of the first mixing part and a floating layer is formed with 0.15 g of the second mixing part to form a multi-layer tablet composite preparation. .

The multilayer tablet tableted by the method of Example 1 is shown in Figure 1.

Example 2: Preparation of multilayer tablet

In a round bottom flask, add 1g of Niclosamide to a solution of 4g of PVP in 50mL of absolute ethanol, stir for about 1 hour, and then dry. 5 g of dried NIC-PVP, 2 g of MgO, and 0.368 g of alginate-Na are dry mixed to form a first mixing section. The second mixing part is manufactured using carbomer (947). For tableting of multi-layered tablets, a drug layer is formed with 0.225 g of the first mixing part and a floating layer is formed with 0.15 g of the second mixing part to form a multi-layer tablet composite preparation. .

Example 3: Preparation of multilayer tablet

In a round bottom flask, add 1g of Niclosamide to a solution of 4g of PVP in 50mL of absolute ethanol, stir for about 1 hour, and then dry. 5 g of dried NIC-PVP, 2 g of MgO, and 0.368 g of xantan gum are dry mixed to form a first mixing section. The second mixing part is manufactured using carbomer (947). For tableting of multi-layered tablets, a drug layer is formed with 0.225 g of the first mixing part and a floating layer is formed with 0.15 g of the second mixing part to form a multi-layer tablet composite preparation. .

Example 4: Preparation of multilayer tablet

In a round bottom flask, add 1g of Niclosamide to a solution of 4g of PVP in 50mL of absolute ethanol, stir for about 1 hour, and then dry. 5 g of dried NIC-PVP, 2 g of MgO, and 0.368 g of chitosan are dry mixed to form a first mixing section. The second mixing part is manufactured using carbomer (947). For tableting of multi-layered tablets, a drug layer is formed with 0.225 g of the first mixing part and a floating layer is formed with 0.15 g of the second mixing part to form a multi-layer tablet composite preparation. .

Example 5: Preparation of multilayer tablet (Na-alginate ratio - 5% in first mixing part)

Add 0.814 g of Niclosamide to a solution of 3.257 g of PVP dissolved in 20 mL of absolute ethanol in a round bottom flask, stir for about 1 hour, and then dry. The first mixing part is prepared by dry mixing dried NIC-PVP, 1.629 g of MgO, and 0.368 g of alginate-Na.

In the second mixing section, 1.5 g of carbomer, 5.7 g of microcrystalline cellulose, 20.0 g of Kollidon SR, 1.25 g of citric acid, and 4.3 g of sodium bicarbonate were weighed and mixed for 20 minutes, then 0.6 g of magnesium stearate was added and mixed for 5 minutes for the second mixing. Manufacture wealth. A drug layer is formed with 0.225 g of the first mixing portion and a floating layer is formed with 0.2 g of the second mixing portion, and a multi-layered tablet combination preparation is tableted.

Example 6: Preparation of multilayer tablet (Na-alginate ratio control, 2.5% in first mixing part)

Add 1.393 g of Niclosamide to a solution of PVP 5.571 dissolved in 24 mL of absolute ethanol in a round bottom flask, stir for about 1 hour, and dry. The first mixing part is prepared by dry mixing dried NIC-PVP, 2.786 g of MgO, and 0.25 g of alginate-Na. The second mixing part is manufactured using carbomer (947). A drug layer is formed with 0.225 g of the first mixing part, and a floating layer is formed with 0.15 g of the second mixing part, and a multi-layer tablet composite preparation is tableted.

Example 7: Preparation of multilayer tablet (Na-alginate ratio control, 7.5% in first mixing part)

Add 1.321 g of Niclosamide to a solution of PVP 5.286 dissolved in 24 mL of absolute ethanol in a round bottom flask, stir for about 1 hour, and dry. Dried NIC-PVP, 2.643 g of MgO, and 0.75 g of alginate-Na are dry mixed to form a first mixing section. The second mixing part is manufactured using carbomer (947). A drug layer is formed with 0.225 g of the first mixing part, and a floating layer is formed with 0.15 g of the second mixing part, and a multi-layer tablet composite preparation is tableted.

Example 8. Manufacture of multilayer tablet (Na-alginate ratio - 5% in first mixing part)

Add 0.814 g of Niclosamide to a solution of 3.257 g of PVP dissolved in 20 mL of absolute ethanol in a round bottom flask, stir for about 1 hour, and then dry. The first mixing section is manufactured by ball milling dried NIC-PVP, 1.629 g of MgO, and 0.368 g of alginate-Na. The second mixing part was prepared using carbomer 974P. After filling 0.225 g of the first mixing portion into the container of the tablet press, the filled drug-containing layer is pre-compressed. After the drug-containing layer is formed, 0.15 g of the second mixing portion is freely dropped and compressed into tablets to form a floating layer thereon.

Example 9. Manufacture of multilayer tablet (Na-alginate ratio - 5% in first mixing part)

Add 0.814 g of Niclosamide to a solution of 3.257 g of PVP dissolved in 20 mL of absolute ethanol in a round bottom flask, stir for about 1 hour, and then dry. The first mixing section is manufactured by ball milling dried NIC-PVP, 1.629 g of MgO, and 0.368 g of alginate-Na. The second mixing part was prepared by dry mixing 0.5 g of carbomer 71G and 0.3 g of sodium carbonate, then adding 0.2 g of carbomer 974P and dry mixing. After filling 0.225 g of the first mixing portion into the container of the tablet press, the filled drug-containing layer is pre-compressed. After the drug-containing layer is formed, 0.15 g of the second mixing portion is freely dropped and compressed into tablets to form a floating layer thereon.

Example 10. Preparation of multilayer tablet

In a round-bottomed flask, 4 g of PVP was dissolved in 50 mL of absolute ethanol, and 1 g of Docetaxel was stirred for 1 hour. Then, 0.9 g of HPMC (6 mPas) and 0.9 g of poloxamer 407 were added and stirred for 1 hour, and the solvent was removed through a rotary evaporator. Completely remove to obtain powder to prepare the first mixing part. The second mixing section is prepared by mixing 42.75 g of carbomer 71G and 42.75 g of Na(CO ₃ ) ₂ , adding 19.5 g of carbomer974P, mixing, and then adding and mixing 5 g of magnesium stearate as a lubricant. After filling 0.3 g of the first mixing portion into the container of the tablet press, the filled drug-containing layer is pre-compressed to form a drug-containing layer. To form a floating layer on top of the drug-containing layer, 0.2 g of the second mixing portion is allowed to fall freely and is compressed into tablets to prepare a multi-layer tablet.

Example 11. Preparation of multilayer tablet

In a round-bottomed flask, 4 g of PVP was dissolved in 50 mL of absolute ethanol, and 1 g of Docetaxel was stirred for 1 hour. Then, 0.9 g of HPMC (6 mPas) and 0.9 g of poloxamer 407 were added and stirred for 1 hour, and the solvent was removed through a rotary evaporator. Docetaxel-PVP-HPMC powder is prepared by completely removing it. 2g of MgO was added to the Docetaxel-PVP-HPMC powder and mixed well to obtain a white powder to form the first mixing section. The second mixing section is prepared by mixing 42.75 g of carbomer 71G and 42.75 g of Na(CO ₃ ) ₂ , adding 19.5 g of carbomer974P, mixing, and then adding and mixing 5 g of magnesium stearate as a lubricant. After filling 0.3 g of the first mixing portion into the container of the tablet press, the filled drug-containing layer is pre-compressed to form a drug-containing layer. To form a floating layer on top of the drug-containing layer, 0.2 g of the second mixing portion is allowed to fall freely and is compressed into tablets to prepare a multi-layer tablet.

Example 12. Preparation of multilayer tablet

Add 0.814 g of Niclosamide to a solution of 3.257 g of PVP dissolved in 20 mL of absolute ethanol in a round bottom flask, stir for about 1 hour, and then dry. The first mixing part was prepared by dry stirring dried NIC-PVP, 1.629 g of MgO, and 0.368 g of alginate-Na. The second mixing part was prepared by dry mixing 5.76 g of carbomer 974P and 3.84 g of sodium carbonate, then adding 0.4 g of magnesium stearate as a lubricant.

After filling 0.3 g of the second mixing portion into the container of the tablet press, the filled floating layer is pre-compressed to form a floating layer. After filling 0.3 g of the first mixing portion on top of the floating layer into the container of the tablet press, the filled drug-containing layer is pre-compressed to form a drug-containing layer. To form a third layer with the same ingredients as the second mixing portion on top of the drug-containing layer, 0.1 g of the second mixing portion is allowed to fall freely and is compressed into a tablet to prepare a multilayer tablet.

Comparative Example 1: Manufacture of single-layer crystal

In a round bottom flask, add 1g of Niclosamide to a solution of 4g of PVP in 50mL of absolute ethanol, stir for about 1 hour, and then dry. The first mixing part was prepared by dry mixing 5 g of dried NIC-PVP and 2 g of MgO. A single-layer tablet is compressed using 0.4 g of the first mixing portion.

Comparative Example 2: Manufacture of single layer crystal

In a round bottom flask, add 1g of Niclosamide to a solution of 4g of PVP in 50mL of absolute ethanol, stir for about 1 hour, and then dry. A first mixing part was prepared by mixing 5 g of dried NIC-PVP, 2 g of MgO, and 0.368 g of sodium alginate. A single-layer tablet is compressed using 0.4 g of the first mixing portion.

Comparative Example 3.

Yomesan (Niclosamide raw material)

Comparative Example 4. Manufacture of single layer crystal

Add 1.357 g of Niclosamide to a solution of 5.429 g of PVP in 26 mL of absolute ethanol in a round bottom flask, stir for about 1 hour, and dry to form NIC-PVP powder. The first mixing part is prepared by dry mixing the dried NIC-PVP powder, 2.714 g of MgO, and 0.5 g of xantan gum. A single-layer tablet is compressed using 0.4 mg of the first mixing portion.

Comparative Example 5.

DOCETAXEL raw materials

Comparative Example 6. Manufacture of single-layer crystal

In a round-bottomed flask, 4 g of PVP was dissolved in 50 mL of absolute ethanol, and 1 g of Docetaxel was stirred for 1 hour. Then, 0.9 g of HPMC (6 mPas) and 0.9 g of poloxamer 407 were added and stirred for 1 hour, and the solvent was removed through a rotary evaporator. Remove it completely. Add 2g of MgO to Docetaxel-PVP-HPMC powder and mix well to obtain a white powder to prepare a single-layer tablet.

Experimental Example 1: In-vivo pharmacokinetic analysis of Example and Comparative Example compositions (Beagle)

In vivo pharmacokinetic analysis was performed using the compositions of Examples 1 to 4 and Comparative Examples 1 and 2. Plasma drug concentration information was obtained by single oral administration of the compositions of Examples 1 to 4 and Comparative Examples 1 and 2 to beagles.

In addition, the compositions of Examples 1 to 4 and Comparative Examples 1 and 2 were each administered once a day at a dose of 40 mg/kg.

The results of Examples 1 to 4 and Comparative Examples 1 and 2 in the above analysis are shown in Figure 2. The graph in Figure 2 shows the concentration of NIC in the plasma of a beagle over time. Specific pharmacokinetic parameters are listed in Tables 2 and 3 below.

Specifically, in the absorption of niclosamide into the body, dispersion and solubility have a significant impact on absorption. In the case of single-layer tablets, due to the viscosity of polyvinyl pyrrolidine (PVP), they cannot be dispersed well in the body and clump up and stay in one random place in the digestive tract. They may not be absorbed in areas with high absorption efficiency and may be digested through the intestines. In this case, their functional Problems may arise where factors are lost. Meanwhile, from the following experimental results, it can be seen that the blood solubility of Examples 1 to 4, which are in the form of a multilayer tablet, is significantly superior to that of Comparative Examples 1 and 2, which are in the form of a single-layer tablet, and that the multi-layered tablet combination preparation of the present invention formulated as a multi-layer tablet is a single-layer tablet. It can be seen that the efficacy of the drug can be further increased.

Time	Niclosamide PO
h	Example 1	Example 2	Example 3	Example 4	Comparative Example 1	Comparative Example 2
0	N.D.	N.D.	N.D.	N.D.	N.D.	N.D.
0.25	508.099	7342.375	109.297	177.727	63.575	21.784
0.5	531.638	-	255.752	148.463	33.273	20.461
One	174.577	-	230.912	42.451	38.443	56.084
2	62.644	-	101.790	66.608	16.888	18.727
4	40.895	-	5.646	21.636	5.818	11.356
6	18.629	-	4.952	1.402	4.524	13.117
8	2.272	-	1.874	1.073	3.243	3.012

PK Parameters	Niclosamide PO
	Example 1	Example 2	Example 3	Example 4	Comparative Example 1	Comparative Example 2
AUC(last)	672.61	N.D.	472.17	279.01	106.46	135.23
AUC(inf)	676.33	N.D.	474.83	280.59	128.66	144.22
Cmax	531.64	N.D.	255.75	177.73	63.58	56.08
Tmax	0.50	N.D.	0.50	0.25	0.25	1.00
t 1/2	1.14	N.D.	0.99	1.03	4.74	2.07
* AUC: ng·h/mL, C max : ng/mL, T max & t 1/2 : h ** ND: Not detected

Experimental Example 2: In-vivo pharmacokinetic analysis of the compositions of Examples, Reference Examples, and Comparative Examples (minipig) The in-vivo pharmacokinetic analysis was conducted using the compositions of Examples 5 to 9 and Comparative Example 3 using minipigs. Plasma drug concentration information was obtained by single oral administration to pigs.

In addition, the compositions of Examples 5 to 9 and Comparative Example 3 were administered at a dose of 500 mg per animal once a day.

In the above analysis, the administration results of Examples 5 to 9 and Comparative Example 3 are shown in Figures 3 and 5. Specific pharmacokinetic parameters are listed in Tables 4 to 7 below. The relationship between tested compositions and AUC is shown in Figures 4 and 6.

As can be seen in Tables 4 to 7 and Figures 3 to 6 below, it was confirmed that the formulated niclosamide exhibited superior bioavailability than the unformulated niclosamide, Yomesan (Comparative Example 3). In addition, it was confirmed that Examples 5 and 6, which were formulated as a multilayer tablet composite preparation, showed significantly better bioavailability than Comparative Example 4, which was in the form of a single-layer tablet, even in the body of minipigs that secreted a large amount of gastric acid. Accordingly, it was confirmed that the present invention, which is a multi-layer tablet using a polymer material that can float in the floating layer of the multi-layer tablet, has a significant effect in improving the bioavailability of the drug compared to a single-layer tablet.

Time				Niclosamide PO 500 mg/head, Mini pig
h	Yomesan (Comparative Example 3)	Example 5	Comparative Example 4
0	N.D.	N.D.	N.D.
0.25	BQL	264.89	10.228
0.5	BQL	204.328	21.354
One	BQL	218.438	57.122
2	BQL	158.881	115.243
4	0.883	59.5	72.029
6	1.941	60.038	15.651
8	4.119	22.794	12.819
12	2.600	7.134	10.535
* Data are represented as the mean concentration (n=2)
* Plasma concentration: ng/mL
* ND: not detected, BQL: below quantitative limit (< 0.5 ng/mL)

PK Parameters				Niclosamide PO 500 mg, Mini pig
	Yomesan (Comparative Example 3)	Example 5	Comparative Example 4
AUC(last)	19.06	866.72	461.16
Cmax	4.7	264.89	115.24
Tmax	7	0.25	2
t 1/2	NC	2.3	10.91
* AUC: ng·h/mL, C max : ng/mL, T max & t 1/2 : h

Time	Niclosamide PO 500mg/KG, Mini pig
h	Example 6	Example 7
0	N.D.	N.D.
0.25	109.623	426.233
0.5	148.505	566.735
One	296.118	465.922
2	439.962	249.543
4	601.514	168.13
6	142.451	100.691
8	148.161	73.274
12	90.857	37.873
* Data are represented as the mean concentration (n=2)
* Plasma concentration: ng/mL
* ND: not detected

PK Parameters	Niclosamide PO
	Example 6	Example 7
AUC(last)	3079.25	1876.04
Cmax	601.51	589.43
Tmax	4	2.25
t 1/2	4.08	2.64
* AUC: ng·h/mL, C max : ng/mL, T max & t 1/2 : h
** NC: Not calculated

Time	Niclosamide PO
h	Example 8	Example 9
0	0.347	0.135
0.25	33.983	71.806
0.5	38.652	108.317
One	73.577	123.827
2	108.398	162.198
4	89.723	86.587
6	54.142	81.489
8	69.751	66.325
12	29.686	19.674
* Data are represented as the mean concentration (n=2) * Plasma concentration: ng/mL

PK Parameters	Niclosamide PO
	Example 8	Example 9
AUC(last)	797.14	969.22
Cmax	144.16	162.20
Tmax	5.00	2.00
t 1/2	5.26	2.69
* AUC: ng·h/mL, C max : ng/mL, T max & t 1/2 : h

Experimental Example 3: In-vivo pharmacokinetic analysis of the compositions of Examples and Comparative Examples (Beagle) In-vivo pharmacokinetic analysis was performed using the compositions of Examples 10 and 11 and Comparative Examples 5 and 6. It has been done. Plasma drug concentration information was obtained by single oral administration of the compositions of Examples 10 and 11 and Comparative Examples 5 and 6 to beagles.

In addition, the compositions of Examples 10 and 11 and Comparative Examples 5 and 6 were each administered at a dose of 50 mg/kg once a day.

The results of Examples 10 and 11 and Comparative Examples 5 and 6 in the above analysis are shown in Figures 7 and 8. The graph in Figure 7 shows the concentration of docetaxel in the plasma of a beagle over time. Specific pharmacokinetic parameters are listed in Tables 10 and 11 below.

The reason for increasing the sustained release of the drug through multilayer tablets as in the example is that if the Cmax of the drug in the blood is high, the probability of exposure to toxicity increases, so by increasing the sustained release of the drug by adjusting the AUC and tmax values, the drug's sustained release in the blood is increased. This is to maintain the concentration in the therapeutic window to maximize its functional role. From the results in Tables 10 and 11 below and Figures 7 and 8, when Cmax is increased by formulating into a multilayer tablet, the AUC and tmax values are also appropriately It was confirmed that the toxicity of the drug was reduced by increasing the dose, but the effect of the drug was sustainable.

In addition, multilayer tablets have the advantage of reducing the number of doses compared to single-layer tablets. In order to maintain the effect of the drug, the drug is continued to be administered when the blood concentration of the drug drops. When formulated as a multilayer tablet, the blood concentration of the drug decreases. It can be seen that the concentration preservation effect in Examples 10 and 11 is significantly superior to that in Comparative Example 6 at the point where .

Time					Docetaxel PO 50 mg/kg
h	Comparative Example 5	Comparative Example 6	Example 10	Example 11
0	N.D.	N.D.	N.D.	N.D.
0.25	0.239	53.817	30.618	28.525
0.5	0.219	94.890	39.726	42.683
One	0.243	29.472	82.114	92.837
2	0.140	28.140	58.857	153.311
4	0.621	12.834	23.556	31.102
6	0.675	9.781	8.745	12.258
8	0.222	14.757	11.547	19.080
* Data are represented as the mean concentration (n=2) * Plasma concentration: ng/mL * ND: not detected

PK Parameters					Docetaxel PO 50 mg/kg
	Comparative Example 5	Comparative Example 6	Example 10	Example 11
AUC(last)	1.86	173.34	248.57	428.53
Cmax	0.50	112.98	82.49	162.15
Tmax	3.50	0.38	0.75	1.50
t 1/2	NC	3.46	2.89	1.89
* AUC: ng·h/mL, C max : ng/mL, T max & t 1/2 : h

Claims (14)

1. A drug-containing layer formed of a first mixing portion including a drug or a pharmaceutically acceptable salt thereof, a crystallization inhibitor, and a polymer for controlling the drug release rate; and

   A multilayer tablet composite formulation comprising a floating layer formed of a second mixing portion containing at least one of a polymer polymerized with poly(meth)acrylate, a polymer polymer polymerized with acrylic acid, and a swellable polymer.
2. In claim 1,

   At least one polymer selected from the group consisting of a polymer polymerized with poly(meth)acrylate, a polymer polymer polymerized with acrylic acid, and a swellable polymer has a tap density of 0.01 g/mL to 1.0 g/mL. , Multilayer tablet combination preparation.
3. In claim 1,

   The first mixing part is a multi-layered tablet combination preparation further comprising at least one compound selected from the group consisting of compounds represented by the following formulas 1 to 3.

   [Formula 1]

   [(M ²⁺ _(10-x) M ³⁺ _x (OH) _m )((A ^n- ) _z )]yH ₂ O

   (In Formula 1, M ²⁺ is a divalent metal cation selected from the group consisting of Mg ²⁺ , Ni ²⁺ , Cu ²⁺ , Co ²⁺ and Zn ²⁺ ,

   M ³⁺ is a trivalent metal cation selected from the group consisting of Al ³⁺ , Fe ³⁺ , V ³⁺ , Ti ³⁺ , Mn ³⁺ and Ga ³⁺ ,

   x is a number in the range between 0 and 10,

   m is a number ranging from 0 to 20,

   A is an anion selected from the group consisting of CO ₃ ^2- , NO _3- ^, Br- ^, Cl- ^, SO ₄ ^2- , HPO ₄ ^2- and ^F- ,

   n is the charge of anion A,

   n is a number ranging from 0.5 to 5, z is a number ranging from 0 to 5,

   y is 0 or a positive number greater than 0.)

   [Formula 2]

   [(M ²⁺ (OH) _2-x )((A ^n- ) _z )]yH ₂ O

   (In Formula 2 above,

   M ²⁺ is a divalent metal cation selected from the group consisting of Mg ²⁺ , Ni ²⁺ , Cu ²⁺ , Co ²⁺ and Zn ²⁺ ,

   x is a number ranging from 0 to 2,

   A is an anion selected from the group consisting of CO ₃ ^2- , NO _3- ^, Br- ^, Cl- ^, SO ₄ ^2- , HPO ₄ ^2- and ^F- ,

   n is the charge number of anion A, n is a number ranging from 0 to 2,

   z is a number ranging from 0 to 1,

   y is 0 or a positive number greater than 0.)

   [Formula 3]

   [(M ²⁺ (O) _2-x )((A ^n- ) _z )]yH ₂ O

   (In Formula 3 above,

   M ²⁺ is Mg ²⁺ , Ni ²⁺ , Cu ²⁺ or Zn ²⁺ ,

   x is a number ranging from 0 to 2,

   A is an anion of CO ₃ ^2- , NO _3- , Br- ^, Cl- ^, SO ₄ ^2- , HPO ₄ ^2- or ^{F- ,}

   n is the charge number of anion A, n is a number ranging from 0 to 2,

   z is a number ranging from 0 to 1,

   y is 0 or a positive number greater than 0.)
4. In claim 3,

   The compound represented by Formulas 1 to 3 is one or more selected from magnesium oxide, hydrotalcite, and magnesium hydroxide, a multilayer tablet combination preparation.
5. In claim 1,

   The first mixing part or the second mixing part further includes one or more compounds selected from the group consisting of an enteric coating agent, a foam generator, and a swelling excipient.
6. In claim 1,

   The high molecular weight polymer obtained by polymerizing acrylic acid is at least one selected from the group consisting of carbomer copolymer type, carbomer homopolymer type, and ammonio methacrylate copolymer type (AMMONIO METHACRYLATE COPOLYMER TYPE), a multi-layered tablet combination preparation.
7. In claim 1,

   The polymer polymer in which poly(meth)acrylate is polymerized is a polymer polymer in which methacrylate is polymerized, a polymer polymer in which ethyl acrylate is polymerized, a polymer polymer in which methacrylate and ethyl acrylate are polymerized, and ethylene glycol is polymerized. polymer polymer, polymer polymer polymerized with methacrylic acid and methyl methacrylate, polymer polymer polymerized with ethylene glycol, polymer polymer polymerized with ammonium methacrylate, dimethylaminoethyl and methacrylate-butyl methacrylate. A multi-layered tablet combination preparation, wherein the rate is one or more selected from polymerized polymers.
8. In claim 1,

   The drugs include Niclosamide, Closantel, rafoxanide, oxyclozanide, Artesunate, Tilorone, Cyclosporine, perhexiline maleate, loperamide, mefloquine, amodiaquine, proscillaridin, phenazopyridine, digitoxin, fen penfluridol, clomiphene, toremifene, digoxin, hexachlorophene, hydroxyprogesterone, thioridazine, salinomycin, Quinacrine, eltrombopag, cepharanthine, ciclesonide, ceritinib (LDK378), dihydrogambogic acid, Ossi osimertinib (AZD-9291), isopomiferin, anidulafungin (LY303366), osajin, lustrombopag, isosajin, Gilteri gilteritinib, berbamine, ebastine, tetradrine, abemaciclib (USAN), ivacaftor, bazedoxifene, mequi Mequitazine, triparanol, droloxifene, dronedarone, chloroquine, hydroxychloroquine, lopinavir, favipiravir ), atazanavir, dexamethasone, Docetaxel, Paclitaxel, Cabazitaxel, Etoposide, Topotecan, Idarubicin, Fluorouracil, Abiraterone, Axitinib, Bosutinib, Cabozantinib, ceritinib, dabrafenib, Erloti erlotinib, lapatinib, midostaurin, neratinib, nilotinib, nintedanib, pazopanib, sonidegib, trad Trametinib, Ascorbic acid, vitamin A, lipoic acid, pramipexole, allopurinol, pentoxifylline, melatonin, probucol (probucol), quercetin, transcrocetinate, acetylcysteine, nicaraven, lodoxamide, 4-n-butylresorcinol (4-n- butylresorcinol, tocopherol, bakuchiol, (+)-catechin, curcumin, hydroxytyrosol, phytol, resorciol (resorcinol), carthamine, luteolin, corilagin, resveratrol, retinol, rutin, hydroquinone, asiaticoside, Madecassoside, ginsenoside, borneol, diosmetin, aspalathin, eugenol, mangostin, pelargonidin ), cyanidin, delphinidin, peonidin, petunidin, malvidin, lutein, quercetin, adenosine, palmit Acid ascorbyl palmitate, ascorbyl glucoside, pyridoxine, thiamine, saponin, secoisolariciresinol, matairesinol, pinoyre Pinoresinol, medioresinol, lariciresinol, syringaresinol, artigenin, enterolactone, enterodiol, arachidonic acid ( arachidonic acid, abietic acid, abscisic acid, α-lipoic acid, azelaic acid, caffeic acid, hydroxybenzoic acid , protocatechuic acid, ellagic acid, ferulic acid, fulvic acid, oleanolic acid, phenolic acid, hydroxycinnamic acid ( hydroxycinnamic acid, vanillic acid, protocatechuic acid, salvianic acid, sinapic acid, tranexamic acid, valeric acid , Veratric Acid, chlorogenic acid, asiatic acid, madecasic acid, suberic acid, hyaluronic acid, ursolic acid. acid), ascorbic acid, salvianolic acid B, pyridine-3-carboxylic acid, ascorbyl palmitate, ascorbyl glucoside ( ascorbyl glucoside, carnitine, pantothenic acid, biotin, folic acid, alliin, glutathione, serine, glycine, alanine ), avenanthramide, threonine, cysteine, valine, leucine, methionine, proline, phenylalanine, tyrosine, Tryptophan, aspartic acid, glutamic acid, asparagine, glutamine, histidine, lysine, arginine, decanal, Retinaldehyde, cinnamaldehyde, catechin-aldehyde, coniferyl aldehyde, syringaldehyde, vanillin, edaravone, idebenone ), coenzyme Q10, ubiquinone, mitoQ, astaxanthin, caffeine, paraxanthine, theophylline, matairesinol ( matairesinol, physcion, propafenone, coumarin, genistein, chalcone, naringenin, bergenin, amentoflavone, Examples include Biochanin A, riboflavin, and Sesamin. One selected from the group consisting of dextran sulfate, ferrous sulfate, ferulic acid-4-O-sulfate and ascorbyl sulfate The above is a multilayer tablet combination preparation.
9. In claim 1,

   The drug is a multilayer tablet combination preparation, wherein the drug is at least one selected from the group consisting of halogenated salicylanilide-based compounds and taxane-based compounds.
10. In claim 9,

    The halogenated salicylanilide group is at least one selected from niclosamide, closantel, rapoxanide, and oxyclozanide,

    A multilayer tablet combination preparation, wherein the taxane series is one or more types selected from docetaxel, paclitaxel, and cabazitaxel.
11. In claim 1,

    The multilayer tablet combination preparation further includes an intermediate layer between the drug-containing layer and the floating layer.
12. In claim 1,

    The crystallization inhibitors include polyvinyl pyrrolidone-based compounds, poloxamer-based compounds, cellulose-based compounds, polyethylene glycol-based compounds, polyoxyethylene sorbitan fatty acid esters compounds, and lecithin compounds. , fatty acid compounds, glycerol fatty acid esters compounds, sorbitan fatty acid esters compounds, oils, sodium dodecyl sulfate, sodium stearyl fumarate ( A multi-layered tablet combination preparation comprising at least one selected from sodium stearyl fumarate, stearic acid, lauric acid, and carrageenan.
13. In claim 1,

    The polymer for controlling the drug release rate includes calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, ethyl cellulose, polyethylene oxide, leucostean gum, guar gum, xanthan gum, acacia gum, and tragacanth gum. gum), alginic acid, sodium alginate, calcium alginate, ammonium alginate, agar, gelatin, polymethmethyl acrylate, polycarbophil, polyvinyl acetate, polyvinylpyrrolidone-polyvinyl acrylate copolymer, polyvinyl Alcohol-polyethylene glycol copolymer, polyvinylpyrrolidone-polyvinylacetate copolymer, bentonite, hectorite, Carrageenan, Ceratonia, Cetostearyl alcohol, hydroxypropyl starch, magnesium A multilayer tablet composite preparation comprising at least one selected from aluminum silicate, polydextrose, poly(methyl vinyl ether/maleic anhydrose), propylene glycol alginate, and saponate.
14. Preparing a first dissolved product by dissolving a crystallization inhibitor and a drug in an organic solvent; preparing a powder of the first melt by drying the first melt; Forming a drug-containing layer using the powder of the first lysate; And forming a floating layer by compressing a second mixed portion containing at least one of a polymer polymer polymerized with poly(meth)acrylate, a polymer polymer polymerized with acrylic acid, and a swellable polymer in the drug-containing layer, thereby forming a floating layer. Method for manufacturing tablet combination preparation.

Images